People: Oncolytics Biotech Inc (ONCY.O)

ONCY.O on Consolidated Issue listed on NASDAQ Capital Market

0.58USD
28 Aug 2015
Change (% chg)

$0.05 (+9.37%)
Prev Close
$0.53
Open
$0.54
Day's High
$0.59
Day's Low
$0.54
Volume
277,228
Avg. Vol
542,508
52-wk High
$1.42
52-wk Low
$0.40

Search Stocks

Summary

Name Age Since Current Position

Bradley Thompson

1999 Executive Chairman of the Board, President, Chief Executive Officer

Kirk Look

2012 Chief Financial Officer

Matthew Coffey

2011 Chief Operating Officer, Director

George Gill

2013 Senior Vice President - Regulatory Affairs & Chief Safety Officer

Alan Tuchman

68 2012 Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs

Mary Dillahunty

2007 Vice President - Intellectual Property

Robert Schultz

2000 Lead Independent Director

Angela Holtham

2014 Director

Edwin Levy

2014 Director

J. Mark Lievonen

2014 Director

James Dinning

62 2004 Independent Director

Linda Hohol

62 2014 Independent Director

Wayne Pisano

2013 Independent Director

Ger van Amersfoort

2006 Independent Director

Nick Hurst

IR Officer

Biographies

Name Description

Bradley Thompson

Dr. Bradley G. Thompson Ph.D., is an Executive Chairman of the Board, President, Chief Executive Officer of Oncolytics Biotech Inc., since April 21, 1999.Dr. Thompson has held the positions of Executive Chairman of the Board, President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. He has provided leadership to various organizations within the biotechnology sector for more than twenty years. Prior to his role with Oncolytics, Dr. Thompson was the Chief Executive Officer of SYNSORB Biotech from 1994 to 1999. From 1983 to 1994, Dr. Thompson worked in a senior role at the Alberta Research Council. He is a current member and Emeritus Chairman of BIOTECanada and sits on the boards of various other biotechnology companies. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.

Kirk Look

Mr. Kirk J. Look CA., is Chief Financial Officer of Oncolytics Biotech Inc. effective November 12, 2012. Mr. Look has served as Oncolytics' Controller since 2003 and has been the Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held senior audit roles with Ernst & Young LLP in both North and South America over an eight year period. He holds a Bachelor of Commerce degree from the University of Calgary and is a Chartered Accountant.

Matthew Coffey

Dr. Matthew C. Coffey Ph.D., is Chief Operating Officer, Director of Oncolytics Biotech Inc. He has been Chief Operating Officer of the Corporation since December 2008. Since April 1999 to December 2008, Dr. Coffey held other senior management positions with the Company and is a co-founder of Oncolytics.Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus.

George Gill

Dr. George M. Gill M.D., is Senior Vice President - Regulatory Affairs & Chief Safety Officer of Oncolytics Biotech Inc. Dr. Gill has been a consultant in clinical research and regulatory affairs to the pharmaceutical and biotechnology industries since he retired from Ligand Pharmaceuticals in 1999. During his 38 years in the industry, he also served in senior executive positions with ICI Pharmaceuticals (now AstraZeneca), Bristol-Myers Squibb, and Hoffmann-La Roche. Dr. Gill holds a B.Sc. in chemistry from Dickinson College in Pennsylvania and an M.D. from the School of Medicine of the University of Pennsylvania in Philadelphia.

Alan Tuchman

Dr. Alan J. Tuchman M.D., MBA., is Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs of Oncolytics Biotech Inc., since September 28, 2012. Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.

Mary Dillahunty

Ms. Mary Ann Dillahunty J.D., MBA., is Vice President - Intellectual Property of Oncolytics Biotech Inc., since 2007. Prior to joining Oncolytics, Ms. Dillahunty was a principal in the law firm of Fish & Richardson, a intellectual property firm in the U.S.

Robert Schultz

Mr. Robert B. Schultz is Lead Independent Director of Oncolytics Biotech Inc., since June 30, 2000. He is former Chairman and Director of Rockwater Capital Corporation, formerly McCarvill Corporation (a financial services company) from 2001 to 2007. Mr. Schultz has held a variety of senior positions, and has participated on various industry-related boards and committees including Director and Chairman of the Investment Dealers Association of Canada.

Angela Holtham

Ms. Angela Holtham is the Director of the company.Ms. Holtham holds a number of governance positions in Canada including: board member & chair of the Audit & Risk Management Committee, Ontario Financing Authority (the Agency that manages the province’s debt and investments); Board director and Audit & Finance Committee member, CMA Canada; and Resources & Audit Committee member, Plexxus (supply chain & IT service provider for 10 GTA hospitals). Ms. Holtham also works part time providing finance executive services on contract after retiring from full time employment after 8 years as the Vice President Finance and CFO of The Hospital for Sick Children in Toronto. Prior to that, she held a number of positions in both the for-profit and not-for-profit sectors, including 20 years with Nabisco Canada, the last 5 as Senior Vice President and CFO.

Edwin Levy

Dr. Edwin Levy Ph.D., is an Independent Director of Oncolytics Biotech Inc., since May 17, 2006. Having served as Senior Vice President of QLT Inc. and a member of the board of BioteCanada, Mr. Levy retired in 2002. Since then Mr. Levy has been an adjunct professor in the Maurice Young Centre for Applied Ethics at the University of British Columbia and has served on a variety of boards including Tides Canada, B.C. Civil Liberties Association, PIVOT Foundation, WelTel, Lawyers’ Rights Watch Canada, and the Neil Squire Society.

J. Mark Lievonen

Mr. J. Mark Lievonen is an Independent Director of Oncolytics Biotech Inc., since April 5, 2004. He is President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, since October 1998. Mr. Lievonen serves on a number of industry and not-for-profit boards including Rx&D, BIOTECanada, the Ontario Institute for Cancer Research and York University, and is a past Chair of BIOTECanada and the Ontario Genomics Institute.

James Dinning

Mr. James F. Dinning is an Independent Director of Oncolytics Biotech Inc., since March 24, 2004. He is Chair of Western Financial Group since September 2004. Mr. Dinning was Executive Vice President of TransAlta Corporation (power generation and wholesale marketing company) from 1997 to 2004. Mr. Dinning is the Chair and Director of other public companies and not for profit entities. He is the former Chair of Export Development Canada. He will complete his four year term as Chancellor of the University of Calgary in June 2014.

Linda Hohol

Ms. Linda Hohol is the director of the company.Ms. Hohol was President of the TSX Venture Exchange from 2002 to 2007 when she retired. Prior to this she had a long and distinguished career with CIBC where she held a number of executive positions including Senior Vice President Alberta and NWT, as well as Executive Vice President Wealth Management. She has held directorships on many for profit, not for profit and crown boards and is also currently a director sitting on the boards of NAV Canada, EllisDon Construction, and Canadian Western Bank.

Wayne Pisano

Mr. Wayne Pisano is Independent Director of Oncolytics Biotech Inc., Effective from May 9, 2013. Mr. Pisano has more than 30 years of experience as a pharmaceutical industry executive and was recognized in 2010 as Pharma Executive of the Year by the World Vaccine Congress. He is currently the president and CEO of VaxInnate a privately held biotech company. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor’s degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.

Ger van Amersfoort

Mr. Ger J. van Amersfoort is an Independent Director of Oncolytics Biotech Inc., since June 15, 2006. He is President and Chief Executive Officer of Novartis Canada, a pharmaceutical company, until his retirement in 2001.

Nick Hurst

Basic Compensation

Search Stocks